INFORMATION FOR THE IMPORTANCE OF AMGROS FOR THE MEDICINAL PRODUCT Imjudo (tremelimumab) Text automatically translated in your browsing language Automatically translated

This prior information notice is an indication of Amgros’ expected conclusion of a commissioning agreement for covered medicinal products in section 3.1. Amgros will enter into commissioning agreements with all interested parties, and Amgros therefore invites all those who potentially want to enter into Amgros' commissioning agreements for the following medicines to express interest by submitting relevant information including price to udbud@amgros.dk. Amgros expects at a later stage to offer the covered medicines as tendered framework agreements on public tender, and the expectation is that the tender will be published within the next 12 months, but this will depend on several factors. Even after the tender has been published, Amgros will continue to enter into commissioning agreements on standard terms with interested parties, but it will not be possible to negotiate terms, including the price of the commissioning agreement, from that point on. The final terms of the tenders will appear in the tender documents when they are published. In relation to section 11.2, it should be noted that the contract notice for the medicinal products covered will be published when the tender is published, and that the date in section 11.2 is purely indicative. Text automatically translated in your browsing language Automatically translated

33600000 - Pharmaceutical products